实用医学杂志 ›› 2023, Vol. 39 ›› Issue (6): 655-659.doi: 10.3969/j.issn.1006⁃5725.2023.06.001

• 临床新进展 •    下一篇

转移性胰腺癌的联合免疫治疗研究进展 

张习杰1 李昕2 周文策1,3   

  1.  兰州大学1 第二临床医学院,2 第一临床医学院(兰州 730000);3 兰州大学第二医院普通外科 (兰州 730000)

  • 出版日期:2023-03-25 发布日期:2023-03-25
  • 通讯作者: 周文策 E⁃mail:zhouwc129@163.com
  • 基金资助:
    国家自然科学基金资助项目(编号:82260555)

Research progress of combined immunotherapy for metastatic pancreas cancer 

ZHANG Xijie*,LI Xin, ZHOU Wence.   

  1. The Second School of Clinical Medicine,Lanzhou University,Lanzhou 730000,China

  • Online:2023-03-25 Published:2023-03-25
  • Contact: ZHOU Wence E⁃mail:zhouwc129@163.com

摘要:

胰腺癌是恶性程度极高的消化系统肿瘤,特别是转移性胰腺癌在临床上表现为病程短、进 展快、病死率高等特点。尽管吉西他滨已成为晚期胰腺癌的标准治疗方案,但治疗效果仍未达到预期。 因此临床上逐渐开展以放化疗、免疫治疗、靶向治疗以及纳米技术等多种治疗手段,但目前对于转移性胰 腺癌单药治疗效果欠佳,研究人员考虑采用联合治疗不断探索新的治疗方案,在临床与基础研究方面进 行了多项针对转移性胰腺癌的联合免疫治疗试验,但总体来讲该领域的治疗方案目前仍存在争议,本文 就近年来转移性胰腺癌的联合免疫治疗研究进展作一综述。

关键词:

转移性胰腺癌, 免疫治疗, 联合治疗

Abstract:

Pancreatic cancer is a highly malignant tumor of the digestive system,especially metastatic pancreatic cancer is characterized by short course of disease,rapid progression and high mortality. Although gem⁃ citabine has become the standard treatment for advanced pancreatic cancer,the therapeutic effect still falls short of the expected survival. Therefore,a variety of treatments such as radiotherapy and chemotherapy,immunotherapy, targeted therapy and nanotechnology have been gradually developed in clinic,however,the effect of single drug therapy for metastatic pancreatic cancer is not satisfactory at present. Researchers are considering the combination therapy to explore new treatment schemes,and there are many clinical and basic studies of combined immunotherapy for metastatic pancreatic cancer. However,the treatment in this field is still controversial. This article reviews the research progress of combined immunotherapy for metastatic pancreatic cancer in recent years.

Key words:

metastatic pancreas cancer, immunotherapy, combined therapy